Surrogate endpoints often expedite the regulatory approval of cancer therapies by providing early signals of efficacy. In resected melanoma, researchers recently examined the validity of recurrence-based metrics. Specifically, they evaluated melanoma surrogate endpoints like disease-free survival (DFS) and distant metastasis-free survival (DMFS) to predict long-term clinical outcomes.

Trial-Level Validation of Melanoma Surrogate Endpoints

A comprehensive study analyzed data from 10,379 patients with AJCC stage I-III melanoma treated at five international centers. The researchers aimed to determine if DFS or DMFS could reliably replace disease-specific survival (DSS). Interestingly, the results showed that both DFS and DMFS had strong correlations with DSS at specific time horizons. Furthermore, trial-level surrogacy for DFS was strongest between 24 and 36 months, with an R² value reaching 0.95. Similarly, DMFS demonstrated high surrogacy for DSS from 24 to 48 months. These findings suggest that recurrence-based endpoints are excellent indicators of cancer-specific mortality in adjuvant settings.

The Challenge with Overall Survival

While the link between recurrence and disease-specific death is clear, the connection to overall survival (OS) remains problematic. The study found that correlations with OS were weak across all horizons. Moreover, this discrepancy often arises because non-cancer deaths or subsequent treatments can dilute the trial-level effects of the primary drug on OS. Consequently, many experts suggest that OS might not be the most suitable primary endpoint for adjuvant melanoma trials. Instead, focusing on DSS or validated surrogates could significantly streamline the evaluation of novel therapies. Additionally, individual-level surrogacy was also evaluated to ensure patient-level consistency.

Common Questions on Melanoma Surrogate Endpoints

What is a surrogate endpoint in oncology?

A surrogate endpoint is a measure, such as disease-free survival, used as a substitute for a clinically meaningful endpoint like overall survival. These endpoints allow researchers to assess treatment benefits faster than waiting for long-term survival data.

Why is overall survival a difficult endpoint in melanoma adjuvant trials?

Overall survival counts all deaths, including those unrelated to cancer. Because melanoma patients may live for many years and receive various subsequent treatments after a recurrence, isolating the effect of a single adjuvant therapy on total mortality is challenging.

Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or a professional physician-patient relationship. Refer to the latest local and national guidelines for clinical practice.

References

1. Orme SE et al. Utility of recurrence-based surrogate endpoints for survival in adjuvant cancer trials: evidence from melanoma. J Natl Cancer Inst. 2026 Jun 15. doi: undefined. PMID: 42295855.


2. Oba K et al. Disease-free survival as a surrogate for overall survival in adjuvant trials for gastric cancer: a meta-analysis. J Natl Cancer Inst. 2013;105(21):1600-1607.